The past 12 months have seen rapid innovation and transformation across the Animal Health industry. Stonehaven Cozmix Group explores advancements in technology and business models shaping the sector’s future, including
- Major launches – Spotlight on new launches in Companion Animal dermatology, cardiology, and parasiticides and Farm Animal vaccines
- Generics Landscape – Evolving competition and market dynamics
- Business Activity – Notable M&A transactions and start-up funding
- Innovative Models – Emerging business approaches reshaping customer engagement and routes to commercialisation
- AI in Animal Health – Growing applications across R&D, diagnostics, and decision-making.
Matthias Hofer
Managing Partner
Stonehaven Cozmix Group
Matthias Hofer is the Managing Partner at Stonehaven Consulting AG with over 15 years of experience in Animal Health. He served on the executive committees of two major Animal Health companies for a total of 7 years. Between 2009 and 2013 he led the global Aqua Health business at Novartis Animal Health (NAH). Later on, he was Global Leader Emerging Business at Elanco and a member of Elanco’s global executive committee. During 2014 and with Elanco’s intention to buy NAH, Matthias served as overall pre-merger integration leader on the Novartis side. In that role, Matthias led a large team and efforts to prepare integration pre-closing overall including carve-out preparations of operations linked to Novartis.
Beatrice Vos, PhD
Partner
Stonehaven Transactions
Kristin Peck
Chief Executive Officer
Zoetis
Kristin Peck is Chief Executive Officer and serves on the Board of Zoetis, the world’s leading animal health company and a member of the Fortune 500. With more than 20 years of experience in life sciences and animal health, Ms. Peck is a purpose-driven leader passionate about driving growth through innovation, superior customer experience and colleague empowerment.
Since becoming CEO in 2020, Ms. Peck has guided Zoetis through a volatile macro environment to deliver superior financial growth – with average organic operating topline growth rates that have outpaced both industry growth and historic company performance. Under her leadership, the company’s portfolio has grown to include 18 blockbuster products – and Zoetis has established a robust pipeline with 12 more potential blockbusters (products with expected future potential sales of $100M+) on the horizon – in addition to delivering industry-leading operating margins.
Ms. Peck’s transformative leadership has earned significant distinctions, including being named to the TIME100 Health (2025), CNBC Changemakers (2024), Barron’s Top CEOs (2022) lists and being recognized as a Fortune Businessperson of the Year (2020).
Before joining Zoetis, Ms. Peck served as Executive Vice President, Worldwide Business Development and Innovation, at Pfizer Inc. and as a member of Pfizer's Executive Leadership Team. Earlier in her career, Ms. Peck held roles at Boston Consulting Group, as well as in private equity and real estate finance at The Prudential Realty Group, The O'Connor Group and J.P. Morgan.
Ms. Peck serves on the boards of BlackRock (NYSE: BLK), Mayo Clinic, and Business Roundtable.
She earned a bachelor's degree from Georgetown University and an MBA from Columbia Business School.
Zoetis
Website: www.zoetis.com
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock producers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $9.3 billion in 2024 with approximately 13,800 employees.
For more information, visit www.zoetis.com
Niamh Gallagher
Program Director - AHNTI
Kisaco Research
Rimma Driscoll
Executive Vice President, Global Strategy, Portfolio Marketing and Business Development, Global BioDevices and Platinum Performance
Zoetis
Rimma Driscoll is an executive in Global Business Development and Strategic Alliances with 20+ years in the field. Rimma has a depth of experience in a broad range of global transactions including JVs,Strategic Alliances, Collaborations, Acquisitions, Divestitures, Licensing Deals, and Partnerships. This experience span from small Discovery deals to multi-billionaire dollar divestitures. Rimma guides Multi-function teams on the external strategies and then leads all aspects of negotiations, and leverages external relationships to bring transactions to closure. She has worked extensively in Pharmaceuticals, Consumer Healthcare and Consumer Products businesses.